Phaseline

Targets › RDRP

RDRP: drug programs, companies and trials

5 programs from 4 companies in 16 trials: 10 Phase 2, 3 Phase 3, 2 Phase 1, 1 Phase 4; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on RDRP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Simcere Pharmaceutical Co., LtdSIM0916 (Deuremidevir Hydrobromide)
RSV RNA-dependent RNA polymerase inhibitor
RDRPPhase 3Respiratory Syncytial Virus InfectionMar 2027
PfizerRemdesivir
RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor
3C, RDRPPhase 3COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 …Sep 2027
Merck & Co. (MSD)Molnupiravir (MK-4482, LAGEVRIO®)
Nucleoside analog inhibitor of viral RNA-dependent RNA polymerase (RdRp)
RDRPPhase 3Coronavirus Disease (COVID-19); Respiratory Syncytial Virus; COVID-19; DengueJan 2031
University of LiverpoolEIDD-2801 (also: MK-4482, Molnupiravir)
Nucleoside analog RNA polymerase inhibitor
RDRPPhase 1Covid19Mar 2027
University of LiverpoolFavipiravir
RNA-directed RNA polymerase inhibitor
RDRPPhase 1Covid19Mar 2027

Conditions

COVID-19 (4) Dengue (2) Covid19 (2) COVID-19 Infection (1) SARS CoV-2 Post-Acute Sequelae (1) COVID - 19 (1) Respiratory Syncytial Virus (RSV) (1) Hematopoietic and Lymphatic System Neoplasm (1) Respiratory Syncytial Virus Infection (1) Coronavirus Disease (COVID-19) (1) Respiratory Syncytial Virus (1)

Modalities

small molecule (3), mixed (2)

Companies

University of Liverpool (2) Pfizer (1) Simcere Pharmaceutical Co., Ltd (1) Merck & Co. (MSD) (1)

Related targets

3C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.